TG Therapeutics' Briumvi meets primary endpoint in Phase 3 trial of single-infusion initiation regimen

• TG Therapeutics presented BRIUMVI data at MSToronto2026, including Phase 3 results supporting a single initial infusion instead of two.
• The ENHANCE trial met its primary goal, showing equivalent drug exposure with comparable infusion reactions across initiation regimens.
• Phase 1 subcutaneous results supported quarterly dosing under evaluation in a fully enrolled Phase 3 trial.
• Seven-year results showed sustained disease control with a consistent safety profile in relapsing multiple sclerosis.
• Initial Phase 1 azer-cel results in primary progressive multiple sclerosis will be presented October 23, 2026; the abstract is available.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261020332469) on October 21, 2026, and is solely responsible for the information contained therein.